Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8SE5

NKG2D complexed with inhibitor 14

Summary for 8SE5
Entry DOI10.2210/pdb8se5/pdb
DescriptorNKG2-D type II integral membrane protein, TRIETHYLENE GLYCOL, DI(HYDROXYETHYL)ETHER, ... (5 entities in total)
Functional Keywordsnkg2d, immune system, immunosuppressant-inhibitor complex, immune system-inhibitor complex, immune system/inhibitor
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight31030.98
Authors
Thompson, A.A.,Grant, J.C.,Karpowich, N.K.,Sharma, S. (deposition date: 2023-04-08, release date: 2023-10-11, Last modification date: 2024-11-20)
Primary citationWang, J.,Nakafuku, K.M.,Ziff, J.,Gelin, C.F.,Gholami, H.,Thompson, A.A.,Karpowich, N.K.,Limon, L.,Coate, H.R.,Damm-Ganamet, K.L.,Shih, A.Y.,Grant, J.C.,Cote, M.,Mak, P.A.,Pascual, H.A.,Rives, M.L.,Edwards, J.P.,Venable, J.D.,Venkatesan, H.,Shi, Z.,Allen, S.J.,Sharma, S.,Kung, P.P.,Shireman, B.T.
Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D).
Bioorg.Med.Chem.Lett., 96:129492-129492, 2023
Cited by
PubMed Abstract: Natural killer group 2D (NKG2D) is a homodimeric activating immunoreceptor whose function is to detect and eliminate compromised cells upon binding to the NKG2D ligands (NKG2DL) major histocompatibility complex (MHC) molecules class I-related chain A (MICA) and B (MICB) and UL16 binding proteins (ULBP1-6). While typically present at low levels in healthy cells and tissue, NKG2DL expression can be induced by viral infection, cellular stress or transformation. Aberrant activity along the NKG2D/NKG2DL axis has been associated with autoimmune diseases due to the increased expression of NKG2D ligands in human disease tissue, making NKG2D inhibitors an attractive target for immunomodulation. Herein we describe the discovery and optimization of small molecule PPI (protein-protein interaction) inhibitors of NKG2D/NKG2DL. Rapid SAR was guided by structure-based drug design and accomplished by iterative singleton and parallel medicinal chemistry synthesis. These efforts resulted in the identification of several potent analogs (14, 21, 30, 45) with functional activity and improved LLE.
PubMed: 37778428
DOI: 10.1016/j.bmcl.2023.129492
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.43 Å)
Structure validation

237735

數據於2025-06-18公開中

PDB statisticsPDBj update infoContact PDBjnumon